Cargando…

The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report

BACKGROUND: The management of Acute Myeloid Leukemia (AML) during pregnancy remains challenging as both the maternal and fetal outcomes should be considered. Several reports suggested that chemotherapy can be administered safely during the second and third trimester of pregnancy. However, the use of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alrajhi, Abdullah M., Alhazzani, Sarah A., Alajaji, Nouf M., Alnajjar, Fouad H., Alshehry, Nawal F., Tailor, Imran K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822434/ https://www.ncbi.nlm.nih.gov/pubmed/31672129 http://dx.doi.org/10.1186/s12884-019-2522-1

Ejemplares similares

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia
por: Ebelt, Nancy D., et al.
Publicado: (2022)

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
por: Tibes, Raoul, et al.
Publicado: (2015)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

Prolonged Survival of a Patient with Chronic Myeloid Leukemia in Accelerated Phase with Recurrent Isolated Central Nervous System Blast Crisis
por: Bin Salman, Ahmed A., et al.
Publicado: (2020)

Imatinib-induced gastric antral vascular ectasia in a patient with chronic myeloid leukemia
por: Alshehry, Nawal F, et al.
Publicado: (2014)

Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML
por: Wang, JingHan, et al.
Publicado: (2020)

Report of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection in Four Patients with Hematological Malignancies Treated at King Fahad Medical City, Riyadh, Saudi Arabia
por: Motabi, Ibraheem H, et al.
Publicado: (2016)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature.
por: Greco, M., et al.
Publicado: (2011)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
por: Aumer, Tina, et al.
Publicado: (2022)

Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
por: Rohon, Peter, et al.
Publicado: (2012)

Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
por: Xu, Ning, et al.
Publicado: (2021)

Chromosomal rearrangements in acute myeloid leukemia (AML)
por: Belloni, E, et al.
Publicado: (2010)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

New agents in acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2020)

AngioCRIME in Acute Myeloid Leukemia (AML)
por: Macintyre, Elizabeth
Publicado: (2017)

Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
por: Dubois, Alix, et al.
Publicado: (2020)

Synthesis and Antiproliferative Activities of 5-Azacytidine Analogues in Human Leukemia Cells
por: Guo, Gang, et al.
Publicado: (2008)

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia
por: Wang, Yanyu, et al.
Publicado: (2022)

Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review
por: Katagiri, Takayuki, et al.
Publicado: (2017)

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia
por: Klosner, Justine, et al.
Publicado: (2021)

Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: Wang, Wei, et al.
Publicado: (2022)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
por: Berthon, Celine, et al.
Publicado: (2020)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
por: Schmutz, Maximilian, et al.
Publicado: (2023)

Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol
por: Šimoničová, Kristína, et al.
Publicado: (2023)

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
por: Bogenberger, J M, et al.
Publicado: (2014)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

Retracted: Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine
por: Cabezón, Marta, et al.
Publicado: (2018)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
por: Chau, David, et al.
Publicado: (2015)

Retracted: Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Transcriptomic Profiles of MV4-11 and Kasumi 1 Acute Myeloid Leukemia Cell Lines Modulated by Epigenetic Modifiers Trichostatin A and 5-Azacytidine
por: Asmaa, Mat Jusoh Siti, et al.
Publicado: (2020)

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
por: Yilmaz, Musa, et al.
Publicado: (2019)

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
por: Winer, Eric S., et al.
Publicado: (2019)

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
por: Chen, Jing, et al.
Publicado: (2020)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rt1k4a5frakioh3t7viktqg3c8